Next Article in Journal
Effects of Anonaine on Dopamine Biosynthesis and L-DOPA-Induced Cytotoxicity in PC12 Cells
Next Article in Special Issue
Synthesis and Characterization of Konjac Glucomannan-Graft-Polyacrylamide via γ-Irradiation
Previous Article in Journal
The First Guaian-12-oic Acid Glucopyranosyl Ester and Other Constituents from Picris rhagadioloides (L.) Desf. (Asteraceae)
A correction was published on 1 April 2008, see Molecules 2008, 13(4), 771.

Molecules 2008, 13(2), 452-474; doi:10.3390/molecules13020452
Review

Application of Prodrugs to Inflammatory Diseases of the Gut

*  and
Center for Oral Health Research, College of Dentistry and Department of Internal Medicine, University of Kentucky, Medical Center, 800 Rose Street, Lexington, KY 40536, USA
* Author to whom correspondence should be addressed.
Received: 26 January 2008 / Revised: 20 February 2008 / Accepted: 21 February 2008 / Published: 27 February 2008
Download PDF [152 KB, uploaded 18 June 2014]

Abstract

Oral delivery is the most common and preferred route of drug administrationalthough the digestive tract exhibits several obstacles to drug delivery including motilityand intraluminal pH profiles. The gut milieu represents the largest mucosal surfaceexposed to microorganisms with 1010-12 colony forming bacteria/g of colonic content.Approximately, one third of fecal dry matter is made of bacteria/ bacterial components.Indeed, the normal gut microbiota is responsible for healthy digestion of dietary fibers(polysaccharides) and fermentation of short chain fatty acids such as acetate and butyratethat provide carbon sources (fuel) for these bacteria. Inflammatory bowel disease (IBD)results in breakage of the mucosal barrier, an altered microbiota and dysregulated gutimmunity. Prodrugs that are chemically constructed to target colonic release or aredegraded specifically by colonic bacteria, can be useful in the treatment of IBD. Thisreview describes the progress in digestive tract prodrug design and delivery in light of gutmetabolic activities.
Keywords: Inflammatory bowel disease; Digestive tract; Drug delivery; microbiota; 5-Aminosalicylic acid; Mycophenolate mofetil; Cysteine and Glutathione prodrugs Inflammatory bowel disease; Digestive tract; Drug delivery; microbiota; 5-Aminosalicylic acid; Mycophenolate mofetil; Cysteine and Glutathione prodrugs
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Oz, H.S.; Ebersole, J.L. Application of Prodrugs to Inflammatory Diseases of the Gut. Molecules 2008, 13, 452-474.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert